This suggests that IL-10RA could serve as an alternative target for efficiently modulating immunity through the regulation of IL-10 signalling and IDO expression, particularly relieving the immune-suppressive interaction of tumour cells/stromal cells and cytotoxic T cells with TME. The gene discussed is IL10RA; the disease is neoplasm.